{"id":44320,"date":"2022-05-25T11:03:23","date_gmt":"2022-05-25T09:03:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/n-lorem-launches-its-patient-empowerment-program-to-support-nano-rare-patients-and-their-families\/"},"modified":"2022-05-25T11:03:23","modified_gmt":"2022-05-25T09:03:23","slug":"n-lorem-launches-its-patient-empowerment-program-to-support-nano-rare-patients-and-their-families","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/n-lorem-launches-its-patient-empowerment-program-to-support-nano-rare-patients-and-their-families\/","title":{"rendered":"n-Lorem Launches its Patient Empowerment Program to Support Nano-rare Patients and Their Families"},"content":{"rendered":"
\n

\nProgram includes new podcast series of informative interviews with thought leaders and lessons from basic science through the continuum of drug development.<\/i>\n<\/p>\n

<\/a><\/p>\n

SAN DIEGO–(BUSINESS WIRE)–n-Lorem, a nonprofit foundation<\/a>, launches its patient advocacy initiative referred to as the \u2018Patient Empowerment Program,\u2019 with the release of its new podcast series. Through this program, n-Lorem hopes to foster a community for nano-rare patients by supporting and empowering them as they navigate understanding their disease. n-Lorem is a non-profit foundation discovering, developing and providing personalized experimental antisense oligonucleotide (ASO) medicines for nano-rare patients (1 to 30 patients worldwide) for free, for life.\n<\/p>\n

\n\u201cOne is a lonely number and most nano-rare patients are exactly that, the single patient in the world with their unique mutation and disease. Whether a nano-rare patient is truly an n-of-1 or a member of a tiny patient population, that patient is entirely isolated. To support these patients and their families, we are creating a community of care, a forum in which our nano-rare patients can share their diagnostic journeys and their hopes that, through n-Lorem, they will have the ultimate personalized treatment developed for their unique disease,\u201d said Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman of n-Lorem Foundation.\n<\/p>\n

\nIn the podcast series, n-Lorem CEO and Founder, Stanley Crooke, will host a variety of interviews with leading physicians, scientists, biotechnology leaders, rare disease advocates and patients and their families. Stan will also host a series of lessons meant to empower through knowledge on such topics as what is a drug, what does a particular organ do, what is antisense and what are biological and chemical systems, to name a few. These lessons will provide basic understanding of many of the topics that nano-rare patients face as they advocate for themselves and their families.\n<\/p>\n

\n\u201cWe call this initiative our Patient Empowerment Program because we hope that is exactly what it does, empower and support our nano-rare patients. This program includes the podcast series we are launching today that focuses exclusively on nano-rare patients and includes a variety of interviews and lessons that will try to fill the knowledge and information void about the nature of nano-rare mutations and diseases,\u201d continued Dr. Crooke.\n<\/p>\n

\nListen today to the first three episodes of the Patient Empowerment Program podcast by visiting www.nlorem.org<\/a> or find them on any podcast listening app. New episodes will be released every second and fourth Wednesday each month. Be sure to subscribe, rate and review.\n<\/p>\n